Company Directory

Biodiversity-derived protein data and AI models for biological design

Basecamp Research is a London-based biotech company that collects biological samples from extreme environments across more than 26 countries, building a proprietary metagenomic database of over ten billion novel protein sequences from more than one million previously unrecorded species. This dataset trains large AI foundation models for designing novel proteins and genetic medicines. The company partners with pharmaceutical, biotechnology, and industrial organisations under ethically-sourced biodiversity agreements.

Drug discovery platform targeting biomolecular condensates

Transition Bio is a biotechnology company developing a drug discovery platform based on the biology of biomolecular condensates, the membrane-less cellular structures implicated in a range of diseases. Using droplet microfluidics and machine learning, the company maps and modulates condensate behaviour to identify small-molecule candidates against targets previously considered undruggable. Lead programmes include a collaboration with Voyager Therapeutics targeting TDP-43 in ALS and frontotemporal dementia, and an internal oncology programme targeting MYC-driven cancers.

Brain-inspired AI platform for multi-target drug discovery

Symbiotic.blue is a pre-seed biotech company developing an AI-driven drug discovery platform that combines generative AI with neuroscience-inspired computational methods. The platform aims to design molecules capable of acting on multiple biological targets simultaneously, with an initial focus on obesity. The company was founded by academics from the Universities of Oxford and Cambridge alongside life sciences industry veterans.

Generative AI platform for TCR therapy design and immune repertoire analysis

Synteny Biotechnology is a biotechnology company developing a platform that combines high-throughput TCR-antigen data generation with generative AI to design precision T cell receptor therapies for cancer. The platform addresses a critical bottleneck in the field, namely the scarcity of paired TCR-epitope interaction data, using protein language models to engineer TCRs with improved tumour specificity and reduced cross-reactivity. The company applies this platform to an internal pipeline of TCR bispecific therapeutic candidates.

Clinical-stage CNS drug discovery using human brain genomics

Cerevance is a clinical-stage biotechnology company developing small molecule therapeutics for neurodegenerative and psychiatric disorders. The company uses its proprietary platform to profile gene expression in specific neuronal and glial cell types from a collection of over 16,000 annotated human brain tissue samples, identifying novel drug targets. Combined with machine learning analysis, this approach supports a pipeline of CNS therapeutics targeting conditions including Parkinson's disease, Alzheimer's disease and ALS.

AI-designed protein fibres as sustainable alternatives to synthetic textiles

Solena Materials is an industrial biotechnology company developing a new class of protein-based fibres for the fashion and performance apparel sectors. Using proprietary deep learning models and computational protein design, the company engineers novel proteins from first principles, which are then produced using engineered microorganisms. The resulting fibres are biodegradable and free of petrochemical inputs, targeting both luxury and high-performance textile applications.

Real-world mental health and dementia data platform for drug development

Akrivia Health is a software company providing a real-world data and AI platform for neuroscience research and drug development. Its dataset of de-identified electronic health records from 6.3 million patients across 20 NHS Trusts covers mental health and dementia conditions, enriched through proprietary natural language processing. Commercial applications include health economics and outcomes research, clinical trial patient recruitment, pharmacovigilance, and drug discovery target identification.

Directed evolution platform engineering microbes for industrial biomanufacturing

Evolutor is a biotechnology company developing directed evolution technologies to enhance microbial performance for industrial biomanufacturing. Its proprietary genetic toolbox links bacterial cell fitness to recombinant protein production rates, generating evolved production strains with substantially improved protein titres. The company offers co-development partnerships and licensing of pre-evolved chassis microbes, and is building towards an automated evolutionary biofoundry integrating genetic engineering, custom hardware, and generative AI.

AI-driven neural data platform for bioelectronic medicine

BIOS Health is a neural engineering company developing an AI-powered platform that reads and interprets peripheral nervous system signals in real time. Its technology links nerve activity to physiological conditions through the discovery of neural biomarkers, supporting the development of personalised neuromodulation therapies and neural digital therapeutics. BIOS serves pharmaceutical and medical device partners, academic research institutions, and NHS clinical programmes targeting cardiovascular, neurological, and autoimmune conditions.

AI-powered infrared diagnostic test for breast cancer recurrence risk

Digistain is a biotechnology company developing MHRA-cleared diagnostic technology for predicting breast cancer recurrence risk. The platform uses infrared spectrometry to generate spectroscopic signatures from tumour biopsy tissue, with AI analysis producing a personalised prognostic score indicating the likelihood of disease recurrence over ten years. The technology is designed as a faster and lower-cost alternative to transcriptomic profiling methods, enabling patient stratification for adjuvant chemotherapy decisions.

AI-powered rare disease case finding for primary care

Mendelian is a digital health software company developing AI-driven tools to support the earlier diagnosis of rare diseases in primary care. Its core product is a Class 1 regulated medical device that analyses electronic health records to identify patients whose symptom profiles are consistent with published diagnostic criteria for hundreds of rare conditions. The platform integrates with NHS clinical workflows and is used by GPs and primary care networks across the UK.

Nanopore platform for single-molecule full-length protein sequencing

Portal Biotech is a biotechnology company developing benchtop nanopore instruments for single-molecule proteomics and metabolomics. Its platform uses bioengineered nanopores coupled with machine learning to sequence intact, full-length proteins at the single-molecule level, capturing protein mutations, modifications and heterogeneity in real time. Evolved from over a decade of academic nanopore research in the Maglia Lab at the University of Groningen, the technology targets drug discovery, diagnostics and biosecurity applications.